Skip to content

Study · Randomized controlled trial · n = 1,071 · 2014

3 results

Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer.

Denham JW, Nowitz M, Joseph D, Duchesne G, Spry NA, Lamb DS, Matthews J, Turner S, Atkinson C, Tai KH, Gogna NK, Kenny L and 14 more

Show all authors

Diamond T, Smart R, Rowan D, Moscato P, Vimieiro R, Woodfield R, Lynch K, Delahunt B, Murray J, D'Este C, McElduff P, Steigler A, Kautto A, Ball J

BJU international11 Feb 2014Cited by 23 (Europe PMC)

PMID24512527 (opens in a new tab)DOI10.1111/bju.12497 (opens in a new tab)PepBankPUB-24512527
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In men with locally advanced prostate cancer, 18 months of leuprorelin did not increase vertebral fractures versus shorter suppression.

    In plain wordsIn men with prostate cancer, longer leuprorelin treatment did not increase vertebral fractures compared with shorter treatment.

    Peptide
    Leuprolide
    Outcome
    No significant changeVertebral fractures at 3 years
    Study

    n = 1,071

    Comparator
    6 months of androgen suppression
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intramuscular · 18 monthsAs given in this study (human).

    Measurements

    Subjects with incident vertebral fractures at 3 years
    132 subjects
    all subjects in the trial, not split by arm

    Source sentences

    Summary
    Their occurrence was not increased by 18 months' AS, nor reduced by ZdA.
    2 context sentences
    Summary · context
    Incident vertebral fractures at 3 years were observed in 132 subjects.
    Summary · context
    Between 2003 and 2007, 1071 men with locally advanced prostate cancer were randomly allocated, using a 2 × 2 trial design, to 6 months i.m. leuprorelin (androgen suppression [AS]) before radiotherapy alone ± 12 months additional leuprorelin ± 18 months zoledronic acid (ZdA), commencing at randomization.
  2. 02HumanRandomized controlled trialSafety outcome

    In men with locally advanced prostate cancer, non-spinal fractures were significantly related to androgen suppression duration.

    In plain wordsIn men with prostate cancer, non-spinal fractures differed with leuprorelin treatment duration.

    Peptide
    Leuprolide
    Outcome
    Direction not reportedNon-spinal fractures
    Study

    n = 1,071

    Comparator
    6 months of androgen suppression
    Analysis
    Secondary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intramuscular · 18 monthsAs given in this study (human).

    Measurements

    Subjects with incident non-spinal fractures
    72 subjects
    all subjects in the trial, not split by arm

    Source sentences

    Summary
    Incident non-spinal fractures occurred in 72 subjects and were significantly related to AS duration but not to ZdA.
    1 context sentence
    Summary · context
    Between 2003 and 2007, 1071 men with locally advanced prostate cancer were randomly allocated, using a 2 × 2 trial design, to 6 months i.m. leuprorelin (androgen suppression [AS]) before radiotherapy alone ± 12 months additional leuprorelin ± 18 months zoledronic acid (ZdA), commencing at randomization.
  3. 03HumanNon-randomized trialSafety outcome

    In men with locally advanced prostate cancer, 6 and 18 months of leuprorelin reduced hip bone density at 2 and 4 years (P < 0.01).

    In plain wordsIn men with prostate cancer, hip bone density fell after both shorter and longer leuprorelin treatment.

    Peptide
    Leuprolide
    Outcome
    DecreaseHip bone mineral density at 2 and 4 years
    Study

    n = 222

    Comparator
    Baseline
    Analysis
    Secondary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intramuscular · 6 and 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Treatment for 6 and 18 months with AS caused significant reductions in hip BMD at 2 and 4 years (P < 0.01)
    1 context sentence
    Summary · context
    Between 2003 and 2007, 1071 men with locally advanced prostate cancer were randomly allocated, using a 2 × 2 trial design, to 6 months i.m. leuprorelin (androgen suppression [AS]) before radiotherapy alone ± 12 months additional leuprorelin ± 18 months zoledronic acid (ZdA), commencing at randomization.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.